Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
GABAPENTIN
Norton Healthcare Limited T/A IVAX Pharmaceuticals UK
300 Milligram
Capsules Hard
2001-05-17
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gabapentin Teva 300 mg Capsules. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Each capsule contains gabapentin 300mg Excipients Each capsule contains soya lecithin 0.0015mg Each capsule contains Yellow Orange S (E110) 0.537mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Orange / Orange, size 0, hard gelatin capsule containing white to off-white powder. The capsule shells are printed with ’93’ and ‘39’. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS NEUROPATHIC PAIN Gabapentin is indicated for the treatment of neuropathic pain. EPILEPSY Monotherapy in adults and children over 12 years of age Gabapentin is used as an antiepileptic indicated for monotherapy or add-on treatment for adults and children over 12 years of age with partial seizures or partial seizures with secondary generalisation, including patients with newly diagnosed seizures. Monotherapy in children under 12 years of age is not recommended until further information is available from controlled trials in this particular age group. Add-on therapy in adults and children age 3 years and above Gabapentin is used as an antiepileptic indicated for add-on treatment for partial seizures or partial seizures with secondary generalisation in adults and children age 3 years and above. For children aged 3 years and above, Gabapentin should be initiated and supervised by a neurological specialist. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Gabapentin Tevais given orally with or without food. When in the judgment of the clinician there is a need for dose reduction, discontinuation, or substitution with an alternative medication, this should be done gradually over a minimum of one week. IRISH MEDICINES BOARD ________ Read the complete document